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Abstract
Background: Phosphatase and tensin homolog deleted in chromosome 10 (PTEN) loss of function is frequently
detected in advanced colorectal cancer. Its detection is thought to have prognostic significance and it is being
considered to predict responsiveness to anti-EGFR therapy. Unfortunately, while immunohistochemical assessment
of PTEN expression is widespread, it lacks standardization and the results are hardly comparable across the available
publications.
Methods: Retrospectively collected, formalin-fixed and paraffin-embedded colorectal tumor tissue samples from 55
patients were combined into tissue microarray (TMA) blocks. We used three different PTEN antibodies to determine
the frequency, intensity and intracellular pattern of PTEN immunohistochemical labeling: Neomarkers, Dako and
CellSignaling. We evaluated the aforementioned parameters in selected regions of colorectal cancers and in their
lymph node metastases by using three scoring methods that take into consideration both staining frequency and
intensity (H1-H3-score). We also evaluated intracellular localization.
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Results: The Dako and CellSignaling antibodies stained predominantly cytoplasms, while the Neomarkers antibody
specifically stained cell nuclei. PTEN H-scores were significantly lower in all tumor areas as compared to the normal
colonic mucosa based on staining with the DAKO and CellSignaling antibodies. Intratumoral regional differences or
differences between matching tumors and metastases were not detected with any of the antibodies. Neither Dako,
neither CellSignaling, nor the Neomarkers antibodies revealed a significant correlation between PTEN expression
and pT, Dukes/MAC and clinical stage. KRAS status, histological grade correlated with PTEN H-scores based on
staining with the Neomarkers antibody. PTEN H-scores did not correlate with MMR status. PTEN H-scores did not
show any correlation with relapse-free survival based on staining with either antibody.
Conclusions: While PTEN expression decreased in colorectal cancer according to two antibodies, neither of the
three applied PTEN antibodies could justify significant correlation with clinicopathological data, nor had prognostic
value. Thus, we might conclude that immunohistochemical PTEN investigation remains a challenge requiring more
standardized evaluation on larger number of cases to clarify its utility as a prognostic and predictive tool in CRC.
The standardization of immunohistochemical method is key in the evaluation process, which is further discussed.
Keywords: Colorectal cancer, PTEN, Protein expression, Intratumoral heterogeneity, Prognostic marker, Predictive
marker, Immunohistochemistry
Background
Colorectal cancer (CRC) is the third most commonly
diagnosed malignant disease in men and second in
women. Its incidence is 1.2 million cases per year, and
608.700 deaths are estimated to have occurred in year
2008 all over the world [1]. So far, prognostic markers are
limited to clinicopathological properties of colorectal
tumors (TNM7 and Dukes/modified by Astler-Coller/
stage classifications, tumor budding and lymphovascular
and perineural invasion). Microsatellite instability (MSI) is
an established predictive marker and determination of
KRAS status is important in the metastatic setting.
Recently, mutations of BRAF, PTEN, PIK3CA and other
RAS genes have been identified to be predictive for
response to anti-EGFR therapy [2, 3].
In the 1990s, two independent studies led to the identifi-
cation of a tumor suppressor gene PTEN (tumor suppres-
sor Phosphatase and TENsin homologue deleted in
chromosome 10) in the chromosomal region 10q23. The
PTEN encodes a protein consisting of 403 amino acids
with double phosphatase specificity for both lipid and
protein substrates. PTEN is expressed both in the cyto-
plasm and in the nucleus, playing different roles at the two
sites. In the cytoplasm, PTEN is mainly involved in the
homeostatic maintenance of PI3K/AKT signaling by coun-
teracting the activity of PI3Ks. Thus PTEN regulates cell
growth directly by inhibiting cell cycle progression, facili-
tating cell death, modulating growth arrest signals, and
indirectly by limiting angiogenesis. Whereas in the nucleus
it is involved in genomic stability and cell cycle regulation
[4]. Its loss of function leads to an upregulation of the
PI3K/AKT signaling pathway, which in turn triggers cell
proliferation and inhibition of apoptosis [5].
Inactivation of PTEN is frequent in multiple cancer
types and it can occur through various genetic alterations:
loss of heterozygosity (LOH), promoter hypermethylation,
point mutations or large chromosome deletions [6–9].
PTEN inactivation has been reported approximately in
20-40 % of CRCs [10, 11]. Mutations seem to be respon-
sible for PTEN-loss in approximately 5-14 % of cases
[10–12]. In a recent study, PTEN protein expression
was found to be lost approximately in 37 % of CRC
without liver metastasis and in 75 % with metastatic
tumor. Additionally, in these cases no PTEN protein
expression was observed in liver metastases [12].
Multiple reports claimed that intranuclear expression
is more important in tumor progression and those
studies have found prognostic value for nuclear PTEN
loss [13–16]. Another study revealed that PTEN pro-
tein localizes to the cytoplasm of both normal and
tumor cells and no correlation of immunostaining
and tumor characteristics could be confirmed [17].
Thus, the role of PTEN as a prognostic factor in
CRC is still controversial [18].
Recently, various studies analyzed the predictive role
of PTEN in targeted therapies. Maintained PTEN
expression in the tumor tissue appeared to be correlated
with response to treatment with the anti-EGFR antibody
cetuximab in independent observations [19–22]. Con-
versely, others found no correlation between PTEN loss
and response to anti-EGFR antibodies [17, 23].
There are several methods available for assessing
PTEN loss, such as Immunohistochemistry (IHC), FISH,
direct sequencing, western-blot, etc. Among these, IHC
is the most widespread since it shows lack of PTEN ex-
pression independently of its cause in an easy, fast and cost
effective way [21, 24, 25]. More studies validated the correl-
ation between PTEN-deletions/mutations and decrease of
protein levels detected by IHC [24, 26–28]. On the other
hand, evaluation of PTENIHC has not been sufficiently
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standardized, neither in the (pre-) analytical nor in inter-
pretation/evaluation phase. Different methods such as posi-
tivity with any kind of staining vs. no reaction [21, 29],
histoscore [23], different cut-off levels for PTEN loss (10 %,
50 %), or similar techniques [22, 30, 31] have been reported.
In a recent study, a robust dichotomized immunohisto-
chemical assessment of PTEN expression was performed.
A high concordance of PTEN expression levels in matched
primary and metastatic CRCs was found and these expres-
sion levels significantly correlated with survival [27, 28].
Although PTEN function might play a crucial role in
colorectal cancer pathogenesis and progression, the
details remain obscure. We still have to understand the
significance of localization (nuclear vs. cytoplasmic), to
determine appropriate threshold or cut-off values for
loss of expression or other ways of meaningful interpret-
ation of IHC . Furthermore, the many commercially
available antibodies might have differential specificity
and sensitivity. In our study, we aimed at addressing
technical, pathobiological and clinically relevant ques-
tions by comparative analysis of PTEN-expression in
CRC. We analyzed intracellular, intratumoral and locor-
egional heterogeneity using three different antibodies
and assessed the prognostic power of those for distant
metastasis-free and overall survival (Fig. 1).
Methods
Fifty-five patients were included in the study (Table 1),
which was approved by the local Institutional Review Board
(IKEB #207/2011). The mean age (± standard deviation)
was 63.45 ± 9.9 years. Upon enrollment, 28/55 (51 %) and
27/55 (49 %) patients were males and females, respectively.
Only tumors with known KRAS status were included in
the study: intentionally fifty-one percent of the patients had
wild-type and 49 % had mutated KRAS status. Formalin-
fixed, paraffin-embedded (FFPE) samples were used. The
following areas were selected from all resection specimens:
Normal colon, border between intact mucosa and tumor,
main tumor mass, invasive front, lymph node metastasis.
These regions were re-assessed histologically and marked
for core punching using the Tissue Microarray Builder in-
strument (Histopathology Ltd., Pécs, Hungary). Cores of
2 mm were taken from all sites mentioned above, including
duplicates from the regions of main tumor mass and inva-
sive front, where feasible.
Immunohistochemical analysis of PTEN was per-
formed on 4 μm thick sections cut from TMA blocks
mounted on adhesive glass slides (SuperFrost UltraPlus
from Gerhard Menzel Ltd., Braunschweig, Germany).
After routine dewaxing antigen retrieval was performed
either in a pH 6.0 Target Retrieval Solution (Dako,
Glostrup, Denmark) for Cell Signaling and Dako
antibodies or in a pH 9.0 buffer of 0.01 M Tris-0.1 M
EDTA for Neomarkers antibody at ~105 °C for 30 min
using an electric pressure cooker (Avair Ida, YDB50-
90D, Biatlon Ltd., Pécs, Hungary).
Brief protocol: Endogenous peroxidase activity was
blocked in a 0.5 % hydrogen peroxide methanol solution
for 20 minutes. Sections were treated in a humidifying
chamber at room temperature using the protein block of
the Novolink kit for 10 min. Three different, validated
[14, 27, 28] and widely used anti-PTEN antibodies were
utilized in our study. Two with cytoplasmic staining pat-
tern: PTEN Clone 6H2.1 Monoclonal Mouse (Code
M3627, Dako, Glostrup, Denmark) in 1:100 dilution,
PTEN 138G6 Rabbit Monoclonal antibody (9559, Cell
Signaling, Boston, MA, USA) in 1:40 dilution. And one
with a nuclear predominance reactivity: PTEN Ab6
28H6 Monoclonal Mouse (MS1797, Neomarkers, Free-
mont, CA, USA) in 1:100 dilution. The sections were
incubated overnight with primary antibodies diluted in
1 % bovine serum albumin in Tris Buffered Saline
(TBS). Subsequently, the slides were treated with the
post-primary reagent of the Novolink kit for 30 minutes
and then with the Novolink Polymer Detection Sys-
tems (Leica-NovoCastra, Newcastle Upon Tyne, UK)
kit for an additional 30 minutes. The slides were
washed between all incubation steps for 3 min in TBS
containing 0.01 % Tween-20. Enzyme activity was visu-
alized using a hydrogen peroxide/DAB (DiAmino Ben-
zidine) solution at pH 4.5 for 3.5 minutes, internal
controls (neural elements and endothel) were utilized
for each reaction. Finally, the slides were counter-
stained with hematoxylin.
large bowel celltumor
Intra-tumoral 
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Intra-cellular 
localization
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Intra-organic 
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Fig. 1 Infographics displaying the aims and methods utilized in the evaluation of PTEN expression in colon carcinoma. We have systematically
considered location in the colorectum, intratumoral localization, intracellular staining pattern using three different antibodies
Ágoston et al. Diagnostic Pathology  (2016) 11:61 Page 3 of 12
Digital imaging of immunostained specimens was per-
formed using a Pannoramic P250beta slide scanner
(3DHistech Ltd., Budapest, Hungary). PTEN expression
patterns were analyzed using the TMA module of the
3DHistech Pannoramic Viewer (1.15.2 RTM) using the
following dimensions: intracellular localization (nuclear,
cytoplasmic, nuclear and cytoplasmic); intensity (0: none,
1: weak, 2: intermediate, 3: strong expression); propor-
tion (0: none, 1: 0-1 %, 2: 2-10 %, 3: 11-33 %, 4: 34-66 %,
5: 67-100 % of respective cells stained). Scores from the
duplicate areas were averaged and raw data was used for
statistical evaluation. For statistical analyses the H-score
for a tumor region was calculated with three different
scoring systems: a) multiplying intensity (i) with fre-
quency (f ) resulting in a 0–15 range (H1-scoretumor
region = itumor region x ftumor region); b) summing intensity
(i) and frequency (f ) resulting in a 0–8 range (H2-score-
tumor region = itumor region + ftumor region); c) H3-score
weighted towards intensity of staining resulting in a
range of 0–15 (Table 2). For prognostic studies all data
from respective tumor regions were averaged into a final
number representing the staining for a case.
Chi-square test, Friedman test and Wilcoxon test were
used for comparison of the expression of PTEN in het-
erogeneous areas of the tumors and across antibodies.
Kruskal-Wallis and Mann–Whitney tests were applied
to compare PTEN expression with conventional prog-
nostic markers. ROC (receiver operating characteristic)
analysis was used for dichotomizing PTEN expression.
Cohen’s kappa was utilized to compare the staining
properties. Kaplan-Meier method was applied to display
the prognostic value supported by log-rank test. The
statistical analysis was performed with SPSS 22 (IBM,
Corp., Armonk, NY, USA). All tests were two-sided and
p-values of less than 0.05 were accepted as statistically
significant.
Table 1 Clinicopathological features of the patients in the
evaluation
Variable Count
Gender Female 27
Male 28
Location of tumor Coecum 9
Ascend. colon 8
Hepatic flexure 5
Transver. Colon 4
Splenic flexure 4
Descend. colon 2
Sigmoid colon 11
Rectosigmoid 5
Rectum 7
Grade NA 8
Low grade 30
High Grade 17
pT NA 11
2 3
3 31
4 10
pN NA 12
0 13
1 15
2 14
Stage NA 11
I 1
II 13
III 20
IV 10
Dukes NA 11
A 1
B 12
C 21
D 10
mAC NA 11
B1 1
B2 9
B3 3
C1 3
C2 12
C3 6
D 10
MMR (IHC) NA 12
MSS 40
MSI 3
Table 1 Clinicopathological features of the patients in the
evaluation (Continued)
KRAS (RFLP + SEQ) mut12 24
mut13 3
Wt 28
Table 2 H3-score. Intersection of corresponding row and
column produces H3-score
Frequency
H3-score 0-1 % 1-10 % 10-33 % 33-66 % 67-100 %
Intensity 1+ 1 2 3 4 5
2+ 6 7 8 9 10
3+ 11 12 13 14 15
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Results
Technical comparison of the evaluated antibodies and
their intracellular staining pattern
First, we tested the expression of PTEN assessed by the
three antibodies in all tumor regions to achieve an over-
all technical comparison (Fig. 2). The frequency, inten-
sity and location of PTEN expression in all stained cores
were evaluated (Table 3). We noted that all antibodies
tended to stain the tissues in a fairly homogenous man-
ner regarding frequency of cells once detecting PTEN,
however the intensity was lower for the DAKO and Cell-
Signaling antibodies, while higher for the Neomarkers.
The latter specifically stained cell nuclei, while the other
two antibodies displayed simultaneous nuclear and
cytoplasmic staining in most specimens. There was a fair
agreement between staining with the Dako and Cell-
Signaling antibodies in frequency, intensity and location,
whereas the Neomarkers antibody showed slight agree-
ment with other antibodies.
Comparison of scoring methods
Next, we calculated H-scores (H1, H2, H3) incorporating
the intensity (0–3) and frequency (0–5) values. These
scoring systems were strongly correlated (ρ = 0.854-0.948)
and no significant difference emerged among them
(p = 0.228-0.666).
PTEN expression assessed with emphasis on intratumoral
distribution
To assess the overall PTEN protein expression at specific
regions we applied all the scoring systems, although,
statistical data is displayed only for the H1-score since no
significant difference was detected among them.
Based on staining with both the DAKO and Cell-
Signaling antibodies, PTEN expression declined from
the normal colon mucosa towards tumor progression
(tumor-normal border → main mass → invasive front
→ lymph node metastasis), though, not significantly.
PTEN H-scores were significantly lower in all examined
tumor areas when compared to the normal colon mu-
cosa (DAKO normal vs. lymph node p = 0,109, vs. main
mass p = 0.005, vs. for all others: border, invasive front
and lymph node metastasis p < 0.001, respectively; Cell-
Signaling normal vs. all tumor regions p < 0.001).
Although, displaying a similar trend, the Neomarkers
antibody did not detect significant difference between
PTEN expression in normal colon and tumor regions
(Fig. 3).
DAKO CellSignaling Neomarker
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Fig. 2 Immunohistochemical images of the investigated regions according to the respective PTEN antibody. The DAKO, CellSignaling
and Neomarkers antibodies staining the normal colon, tumor-normal border, main tumor mass and invasive front of the colorectal tumors
(20x magnification)
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There was no significant difference between PTEN
expression either between different tumor regions or
between matched lymph node metastasis and tumor
mass with any of the three antibodies.
PTEN expression assessed according to tumor localization
in the large bowel
PTEN expression levels assessed by the three antibodies
were compared between the various regions of the
colorectum (Fig. 4). H-scores of the individual regions
(cecum, ascending colon, hepatic flexure, transverse
colon, splenic flexure, descending colon, sigmoid colon,
rectum) and colon sides (right vs. left vs. rectum) did
not show any statistically significant differences in PTEN
expression with any of the three antibodies.
Clinicopathological evaluation
As no significant differences in PTEN protein expression
were noted across the selected tumor areas (Fig. 3), we
calculated the average score for each case by the follow-
ing equation: H-scorecase = (H1-scoretumor-normal border +
H1-scoremain tumor mass + H1-scoreinvasive front)/3. Next,
we analyzed the correlation between the clinicopatholog-
ical data and the H-scorescase (Fig. 5).
Neither DAKO (D), neither CellSignaling (C) nor the
Neomarkers (N) antibodies detected any correlation of
PTEN expression and pT (p/D/= 0.817, p/N/= 0.175, p/
C/= 0.611). Similarly, no significant correlation was
noted for Dukes (p/D/= 0.454, p/N/= 0.896, p/C/=
0.824), Dukes-MAC (p/D/= 0.718, p/N/= 0.728, p/C/=
0.990) and for clinical stage either (p/D/= 0.806, p/N/=
0.984, p/C/= 0.727). In contrary, KRAS status correlated
Table 3 Expression of PTEN according to the three antibodies
DAKO Neomarkers Cell Signaling
Frequency Valid Percent Frequency Valid Percent Frequency Valid Percent
Frequency 0 12 5.6 0 2 .8 0 7 3.0
1 = 0-1 % 13 6.0 1 = 0-1 % 3 1.3 1 = 0-1 % 4 1.7
2 = 2-10 % 12 5.6 2 = 2-10 % 27 11.4 2 = 2-10 % 2 .8
3 = 11-33 % 8 3.7 3 = 11-33 % 37 15.6 3 = 11-33 % 5 2.1
4 = 34-66 % 23 10.6 4 = 34-66 % 27 11.4 4 = 34-66 % 15 6.3
5 = 67-100 % 148 68.5 5 = 67-100 % 141 59.5 5 = 67-100 % 204 86.1
Total 216 100.0 Total 237 100.0 Total 237 100.0
Statistics DAKO vs. NEOM Value p NEOM vs. CELLS Value p CELLS vs. DAKO Value p
Kappa .067 .066 Kappa .056 .066 Kappa .264 .000
Chi-square 0.064 Chi-square .286 Chi-square .000
Intensity 0 12 5.6 0 2 .8 0 7 3.0
1 = + 158 73.1 1 = + 41 17.3 1 = + 146 61.6
2 = ++ 29 13.4 2 = ++ 61 25.7 2 = ++ 33 13.9
3 = +++ 17 7.9 3 = +++ 133 56.1 3 = +++ 51 21.5
Total 216 100.0 Total 237 100.0 Total 237 100.0
Statistics DAKO vs. NEOM Value p NEOM vs. CELLS Value p CELLS vs. DAKO Value p
Kappa .051 .051 Kappa .082 .014 Kappa .305 .000
Chi-square .024 Chi-square .260 Chi-square .000
Location 0 11 5.0 0 2 .8 0 8 3.2
1 = nucl 5 2.3 1 = nucl 241 99.2 1 = nucl 2 .8
2 = cytop 44 19.9 2 = cytop 0 .0 2 = cytop 22 8.7
3 = nucl+cytop 161 72.9 3 = nucl+cytop 0 .0 3 = nucl+cytop 220 87.3
Total 221 100.0 Total 243 100.0 Total 252 100.0
Statistics DAKO vs. NEOM Value p NEOM vs. CELLS Value p CELLS vs. DAKO Value p
Kappa -.001 .712 Kappa -.005 .000 Kappa .390 .000
Chi-square .480 Chi-square .000 Chi-square .000
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with PTEN expression only based on staining by the
Neomarkers antibody (p/D/= 0.713, p/N/= 0.029, p/C/=
0.062): PTEN expression detected by the Neomarkers
antibody was lower in KRAS mutant tumors bearing the
mutation in exon 13. On the other hand, staining by the
CellSignaling antibody displayed opposite trend without
statistical significance: lower expression in KRASmut at
exon 12 and WT tumors as compared to the few KRAS-
mut at exon 13 carcinomas. Similar correlation of grade
was seen only with N, showing higher expression in high
grade tumors, while equal distribution in all grades was
found with D and C (p/D/= 0.832, p/N/= 0.040, p/C/=
0.099). PTEN expression did not correlate with MMR
status (p/D/= 0.731, p/N/= 0.315, p/C/= 0.679) based on
staining with any of the three antibodies.
For the assessment of prognostic power of PTEN
immunohistochemistry we utilized a dichotomizing/bi
nary system on the basis of two methods: A, according
to published approaches, maintained PTEN expression
(PTEN-normal) was assigned when PTEN expression of
the tumor was similar to surrounding normal mucosa
[24, 26, 28, 30], whereas PTEN loss was assigned when
tumor regions had significantly lower PTEN expression
than the surrounding normal mucosa (Additional file 1:
Figure S1). B, for a more objective assessment, we have
utilized ROC analysis to determine the optimal thresh-
old of PTEN expression detected by immunohistochem-
istry. Cut-off point of PTEN possesses sensitivity of 61 %
and specificity of 70 %, with low area under the curve
(AUC: 0.440-0.626). Based on the above-described ana-
lyses, no prognostic power of D, C and N antibodies was
detected in any setting.
Discussion
The tumor suppressor gene PTEN is gaining attention
regarding its role in multiple carcinomas. In CRC, the
possible prognostic and predictive value of PTEN immu-
nohistochemical staining is highly investigated, but re-
mains controversial [18, 32, 33].
Whereas more silencing mechanisms (mutations, LOH,
promoter hypermethylation, copy number changes or
miRNAs) can lead to decreased PTEN-expression or
PTEN-loss, one of the most widespread detection method
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Fig. 3 Expression levels of PTEN in normal colon mucosa, in various
areas of primary tumor and in metastases. PTEN IHC was performed with
antibodies from DAKO, CellSignaling and Neomarkers. Specimens were
digitally imaged and H-scores were calculated based on a combination
of staining intensity and frequency as described in methods. Data shown
are mean PTEN (±95 % confidence interval) H-score values determined
by the three antibodies and at the tumor regions indicated. Asterisk (*)
marks significant difference (DAKO normal vs. border p= 0.005, all others
p< 0.001 for all others) between the normal colon and all tumor regions
detected by the DAKO and the CellSignaling antibody. There were no
significant differences based on staining with the Neomarkers antibody
Fig. 4 PTEN expression according to the location of the tumor in the large bowel. Mean expression of PTEN (±95 % confidence interval)
according to the three antibodies considering location of the tumors in the colorectum
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is the immunohistochemistry due to its cost-
effectiveness and relative independence from the cause
of PTEN loss and the relatively simple procedure.
PTEN expression analysis by IHC has been used by
the majority of recent studies [18], although, these are
not standardized.
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Fig. 5 Correlation of PTEN expression and clinicopathological parameters. Mean of PTEN expression investigated by the 3 antibodies according to
pT, pN, Dukes-mAC stages and KRAS status
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Possible differences may occur during the pre-analytical
phase (such as tissue sampling method, time of ischemia,
fixation time, temperature, dehydration conditions) during
the IHC staining process (antibody concentration, diluent,
the different antibody sensitivity and specificity between
tissue types, detection method) and during the interpret-
ation/evaluation phase (different methods such as positiv-
ity with any kind of staining vs. no reaction, histoscore,
different cut-off levels for PTEN loss, intracellular
localization of PTEN), as well. Considering the results of
previous studies, we focused on two key points: antibody
type and scoring method. There are more studies validat-
ing the different methods assessing PTEN-loss [27, 30],
the most valuables are the sequential studies of Sangale et
al. They firstly described a thorough validation process of
ten different anti-PTEN clones on different cell-lines and
samples of known PTEN-status concluding onto the best
clones, while in their concomitant study with the ‘winner’
antibody they could demonstrate PTEN’s prognostic role
in a set of metastatic CRCs. [27, 28]
We basically followed their approach using their two best
ranked antibodies (Dako and CellSignaling) together with
on also widely used ‘nuclear’ clone (Neomarkers). As no
accepted PTEN-IHC receipt exists now, we used internal
controls as suggested by recently mentioned authors.
There are more different scoring methods for PTEN-
status with different number of positivity-classes or
dichotomization upon the percentage of positive tumor
cells compared to internal control. As different studies
with different PTEN-classifications and different patient-
sets are hardly comparable we decided to use more
evaluation methods and to compare the results of those
on a common set of cases.
Our study evaluated intracellular and intratumoral
heterogeneity of PTEN immunohistochemical detection
in CRC using three different antibodies: DAKO (D),
Neomarkers (N) and CellSignaling (C). Although differ-
ent protocols for PTEN immunostaining have been de-
scribed [27, 30], these are still not standardized. We
adopted three combined scoring methods by using three
main dimensions: intracellular localization, intensity and
frequency of the PTEN expression. To our knowledge,
these methods have not been used before. Our goal was
to evaluate the staining characteristics with three com-
mercially available antibodies and to correlate those with
tumor localization in the colorectum and with clinico-
pathological data. We attempted to evaluate the prog-
nostic role and clinical applicability of PTEN protein
expression in CRC.
There was a moderate correlation between staining
with the Dako and the CellSignaling antibodies both in
frequency and in intensity, whereas staining with the
Neomarkers antibody did not show correlation with
other antibodies. The discordant results of N with C and
D can be explained partly by the different staining char-
acteristics of the N-antibody favoring nuclear staining,
while C and D produced predominantly cytoplasmic
staining. Recent validation work by Sangale et al. found
that the Neomarkers antibody had low sensitivity and
specificity for the detection of PTEN loss [27].
In our study, PTEN expression was significantly lower
in all examined tumor areas when compared to the nor-
mal colon mucosa by using either DAKO or CellSignal-
ing antibody. The Neomarkers antibody showed similar
trend, but without reaching significance. Staining for
PTEN levels with all three antibodies exhibited a trend
(although without statistical significance) along the
tumor edge → main tumor mass → invasive front →
lymph node metastasis sequence, which is in agreement
with a potential role for PTEN in carcinogenesis and
progression. Our findings are in line with literature data
[13, 14, 25, 31]. However, our study provides novel
insight by reporting on the relative performance of three
commonly used antibodies. These novel data should
raise caution regarding the interpretation of results
obtained using various antibodies, and call for a need to
establish standardized and validated protocols to utilize
this potentially valuable tool.
We couldn’t find significant difference of staining in-
tensity within tumor regions and matched lymph node
metastasis. We only observed a trend of gradual de-
crease towards the invasive front. This is in contrast to
multiple studies claiming rather heterogeneous PTEN
expression in CRC based on detection by IHC [18, 27].
Furthermore, PTEN expression was similar in main
tumor mass and in lymph node metastasis. These data
are in agreement with a finding of strong concordance
between PTEN status in primary CRC and correspond-
ing liver metastases [12, 28]. We found no statistically
significant differences between the localization of tumor
in the large bowel and PTEN expression. In contrast,
others found lower PTEN-expression in distal tumors as
compared to proximal tumors [25, 34, 35].
In our study, we found no correlations between clini-
copathological parameters such as pT, Dukes, clinical
stage and PTEN expression levels as determined by the
three different antibodies.
Variable results have been reported regarding correl-
ation between PTEN expression and clinicopathological
parameters of CRC [13, 15, 36]. Significant correlation
of advanced TNM stage with a loss of PTEN expression
was referred by Sawai et al. [12]. Taniyama et al. found
no correlation between PTEN expression and stage or
grade in sporadic CRC [17]. So, there are variable results
reported regarding correlations between clinical stage
and/or prognosis and PTEN expression levels deter-
mined by IHC. Based on our data, we reason that this
might be due to a differential performance of various
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antibodies used for detection, and may be due to a lack
of standardization with regard to both the technical per-
formance of staining and analytic techniques.
In our study, KRAS status was correlated with PTEN
expression only based on staining with the Neomarkers
antibody and there was no correlation found with either
the DAKO or the CellSignaling antibody. However, this
was detected in those few cases which possessed muta-
tion on exon 13. In this respect the negative findings
with the latter two antibodies are in agreement with
other studies that did not find statistically significant
correlation between PTEN expression and mutations of
PIK3CA or KRAS/NRAS/BRAF in primary CRC tissue
samples or in their liver metastases [28]. No correlation
was found between grade and PTEN status with any
antibodies. These findings are similar to what was found
by Lin and Jin et al. [37, 38].
The occurrence of MSI in sporadic CRC is 10-15 % [39].
A study identified the presence of frameshift mutations of
these poly(A) tracts in colorectal cancers, suggesting that
the PTEN gene might be a target of MSI-based colorectal
carcinogenesis [40]. In our patient population the occur-
rence of MSI phenotype was 5.5 % and there was no
significant correlation between MSI phenotype and
PTEN-expression. However, the low number of MSI tu-
mors in our study renders this comparison underpowered.
When assessing the prognostic role of PTEN expres-
sion by dichotomizing CRCs to PTEN-normal and
PTEN-loss cases, we found that PTEN-loss determined
by any antibodies was not prognostic for relapse-free
survival in any setting. Correspondingly, the ROC ana-
lysis failed to split the cohort on the basis of PTEN H-
score. Bohn et al. found both prognostic and predictive
differences between either colonic or rectal localization
of PTEN loss: their separate analysis of rectal and
colonic cancers revealed a significant association be-
tween PTEN status and overall survival in rectal cancers
only [41], however, in our analysis rectal tumors were
underrepresented. On the other hand, others - in line
with our results - did not find any association between
PTEN loss and prognosis [28, 37, 38].
Conclusion
We utilized three different antibodies for the immunohisto-
chemical assessment of PTEN expression in 55 colorectal
cancer cases, with an emphasis on identifying locoregional,
intratumoral and intracellular staining patterns. Our
approach applied three histoscore methods combining the
intensity and frequency of PTEN staining. Dako and
CellSignaling antibodies had significantly concordant cyto-
plasmic staining pattern with each other and both detected
a decrease in PTEN-expression in all tumor areas com-
pared to normal mucosa, but found no correlation with
clinicopathological parameters. IHC staining with the
Neomarkers antibody indicated distinctly nuclear pattern
and did not justify significant decrease of PTEN-expression
in tumor vs. normal. Neomarkers H-scores did not correl-
ate with pT, Dukes, or TNM stage, but did correlate with
K-RAS status. Neither applied antibody showed prognostic
value in any settings. In our study, the different staining
properties of the 3 antibodies made the comparison hard,
even if sophisticated evaluation was applied with three
different H-scores or a dichotomization for PTEN-loss with
different thresholds.
We concluded that the prognostic, predictive potential
and clinicopathological relevance of immunohistochemi-
cal determination of PTEN status remains uncertain. To
overcome this issue more standardized studies relying on
previous validation studies (like Sangale et als’) on more
numerous and homogenous patients with standardized
protocols should be performed possibly involving digital
evaluation methods for immunohistochemistry.
Additional file
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with PTEN loss. (PDF 1033 kb)
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